Stocks · News reference
Silo Pharma Says Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Application Covering SPC-15, Intranasal 5-HT4 Receptor Agonist Targeting PTSD And Other Stress-Induced Psychiatric Disorders
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic programSARASOTA, FLA., Aug. 18, 2026 (GLOBE NEWSWIRE) --
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting On August 18, 2026; Issues 165,000 Shares As Consideration For Asset Purchase
-SEC Filing
8-K filing — Silo Pharma, Inc. (SILO)
Filed: 2026-08-19 AccNo: 0001213900-26-091783 Size: 235 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.6 million. As per the news, the Q2 earnings report came